| Literature DB >> 31432173 |
Jinwen Zhu1, Xinliang Zhang1, Wenjie Gao1, Huimin Hu1, Xiaodong Wang1, Dingjun Hao1.
Abstract
Accumulating evidence has indicated that noncoding RNAs are involved in intervertebral disc degeneration (IDD); however, the competing endogenous RNA (ceRNA)‑mediated regulatory mechanisms in IDD remain rarely reported. The present study aimed to comprehensively investigate the alterations in expression levels of circular RNA (circRNA), long noncoding RNA (lncRNA), microRNA (miRNA/miR) and mRNA in the nucleus pulposus (NP) of patients with IDD. In addition, crucial lncRNA/circRNA‑miRNA‑mRNA ceRNA interaction axes were screened using the GSE67567 microarray dataset obtained from the Gene Expression Omnibus database. After data preprocessing, differentially expressed circRNAs (DECs), lncRNAs (DELs), miRNAs (DEMs) or genes (DEGs) between IDD and normal controls were identified using the Linear Models for Microarray data method. A protein‑protein interaction (PPI) network was constructed for DEGs based on protein databases, followed by module analysis. The ceRNA network was constructed based on the interaction between miRNAs and mRNAs, and lncRNAs/circRNAs and miRNAs. The underlying functions of mRNAs were predicted using the Database for Annotation, Visualization and Integrated Discovery database. The present study identified 636 DECs, 115 DELs, 84 DEMs and 1,040 DEGs between patients with IDD and control individuals. PPI network analysis demonstrated that Fos proto‑oncogene, AP‑1 transcription factor subunit (FOS), mitogen‑activated protein kinase 1 (MAPK1), hypoxia inducible factor 1 subunit α (HIF1A) and transforming growth factor β1 (TGFB1) were hub genes and enriched in modules. Metastasis‑associated lung adenocarcinoma transcript 1 (MALAT1)/hsa_circRNA_102348‑hsa‑miR‑185‑5p‑TGFB1/FOS, MALAT1‑hsa‑miR‑155‑5p‑HIF1A, hsa_circRNA_102399‑hsa‑miR‑302a‑3p‑HIF1A, MALAT1‑hsa‑miR‑519d‑3p‑MAPK1 and hsa_circRNA_100086‑hsa‑miR‑509‑3p‑MAPK1 ceRNA axes were obtained by constructing the ceRNA networks. In conclusion, these identified ceRNA interaction axes may be crucial targets for the treatment of IDD.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31432173 PMCID: PMC6755180 DOI: 10.3892/mmr.2019.10569
Source DB: PubMed Journal: Mol Med Rep ISSN: 1791-2997 Impact factor: 2.952
Top upregulated and downregulated differentially expressed circRNAs, lncRNAs, miRNAs and mRNAs identified from Gene Expression Omnibus microarray datasets.
| A, circRNAs | ||
|---|---|---|
| RNA | logFC | FDR |
| hsa_circRNA_101852 | 2.98 | 3.92×10−15 |
| hsa_circRNA_101853 | 2.93 | 6.98×10−16 |
| hsa_circRNA_101139 | 2.92 | 6.98×10−16 |
| hsa_circRNA_103890 | 2.86 | 1.72×10−15 |
| hsa_circRNA_400019 | 2.84 | 3.87×10−14 |
| hsa_circRNA_102324 | 2.78 | 1.00×10−15 |
| hsa_circRNA_104703 | 2.72 | 1.24×10−15 |
| hsa_circRNA_104600 | 2.68 | 7.51×10−15 |
| hsa_circRNA_100604 | 2.68 | 1.57×10−15 |
| hsa_circRNA_100018 | 2.61 | 1.67×10−15 |
| hsa_circRNA_103410 | 2.59 | 6.98×10−16 |
| hsa_circRNA_000200 | 2.56 | 2.32×10−14 |
| hsa_circRNA_100086 | 2.32 | 7.03×10−14 |
| hsa_circRNA_102348 | 1.95 | 9.57×10−14 |
| hsa_circRNA_102399 | 1.63 | 4.92×10−12 |
| hsa_circRNA_101645 | −3.30 | 1.60×10−14 |
| hsa_circRNA_104508 | −3.26 | 2.19×10−13 |
| hsa_circRNA_102116 | −3.18 | 1.92×10−14 |
| hsa_circRNA_103838 | −3.06 | 6.98×10−16 |
| hsa_circRNA_101557 | −3.05 | 1.96×10−14 |
| TRPC7-AS1 | 6.61 | 6.55×10−8 |
| MIR4458HG | 1.40 | 5.56×10−3 |
| GAS5 | 1.40 | 4.30×10−2 |
| CBR3-AS1 | 1.40 | 3.05×10−4 |
| ADPGK-AS1 | 1.40 | 2.67×10−3 |
| SNHG5 | 1.40 | 2.67×10−2 |
| ADARB2-AS1 | 1.391 | 4.17×10−3 |
| LINC00431 | 1.39 | 4.68×10−4 |
| MCCC1-AS1 | 1.39 | 8.89×10−3 |
| MALAT1 | 1.07 | 6.58×10−4 |
| HOTAIR | −7.21 | 6.47×10−8 |
| LINC00957 | −6.28 | 7.33×10−9 |
| VPS13A-AS1 | −6.01 | 1.81×10−8 |
| IL10RB-AS1 | −5.54 | 9.48×10−9 |
| MAPT-AS1 | −5.12 | 6.53×10−9 |
| LINC00689 | −3.63 | 2.87×10−5 |
| EFCAB6-AS1 | −3.39 | 2.96×10−8 |
| HAND2-AS1 | −3.21 | 3.47×10−4 |
| LINC00884 | −3.12 | 5.11×10−5 |
| LINC01405 | −3.04 | 9.52×10−4 |
| hsa-miR-4287 | 5.81 | 4.50×10−3 |
| hsa-miR-3150a-3p | 5.03 | 1.24×10−5 |
| hsa-miR-3157-3p | 4.90 | 1.00×10−2 |
| hsa-miR-660-5p | 4.80 | 1.99×10−34 |
| hsa-miR-887-3p | 4.05 | 1.05×10−4 |
| hsa-miR-5010-5p | 4.03 | 2.66×10−2 |
| hsa-miR-933 | 3.43 | 7.39×10−3 |
| hsa-miR-3127-5p | 3.35 | 4.45×10−3 |
| hsa-miR-4450 | 3.24 | 2.23×10−3 |
| hsa-miR-516a-5p | 3.15 | 2.29×10−4 |
| hsa-miR-1184 | −4.85 | 5.44×10−4 |
| hsa-miR-125b-1-3p | −4.69 | 4.44×10−4 |
| hsa-miR-486-3p | −4.39 | 8.00×10−3 |
| hsa-miR-3648 | −3.76 | 6.14×10−46 |
| hsa-miR-196b-5p | −3.43 | 1.00×10−2 |
| hsa-miR-155-5p | −3.22 | 2.00×10−2 |
| hsa-miR-302a-3p | −1.93 | 2.00×10−2 |
| hsa-miR-519d-3p | −1.81 | 4.00×10−2 |
| hsa-miR-509-3p | −1.78 | 3.00×10−2 |
| hsa-miR-185-5p | −1.53 | 1.00×10−2 |
| HBB | 8.41 | 3.87×10−9 |
| HBA1 | 8.19 | 8.62×10−11 |
| COL1A2 | 7.01 | 3.41×10−10 |
| PTP4A3 | 6.98 | 7.31×10−7 |
| RBM38 | 6.70 | 1.72×10−9 |
| MFAP4 | 6.19 | 7.41×10−9 |
| GREM1 | 5.77 | 4.49×10−8 |
| NKG7 | 5.55 | 1.13×10−9 |
| TREM1 | 5.47 | 1.12×10−9 |
| LUM | 5.36 | 3.28×10−9 |
| PHLDB2 | −7.09 | 2.99×10−8 |
| TMEM177 | −6.96 | 1.12×10−9 |
| KIAA0319 | −6.95 | 5.16×10−10 |
| ERLIN1 | −6.89 | 6.61×10−10 |
| APOD | −6.47 | 4.61×10−7 |
| SLF2 | −6.45 | 5.61×10−10 |
| NDRG4 | −6.44 | 4.91×10−10 |
| GUCY1A3 | −6.43 | 9.45×10−10 |
| PLAGL1 | −6.41 | 1.67×10−7 |
| ATP8B3 | −6.32 | 7.34×10−9 |
Positive logFC values indicate upregulated expression in IDD samples compared with in control samples, whereas negative logFC values indicate downregulated expression in IDD samples compared with in control samples. All microarray datasets were retrieved from public Gene Expression Omnibus databases, including GSE67566 (12,13) for circRNA expression; GSE63492 (12,13) for miRNA expression and GSE56081 (12,14) for mRNA-lncRNA expression. circRNA, circular RNA; FC, fold change; FDR, false discovery rates; IDD, intervertebral disc degeneration; lncRNA, long noncoding RNA; miRNA, microRNA.
Figure 1.Hierarchical clustering and heat map analysis of differentially expressed (A) circRNAs, (B) lncRNAs, (C) miRNAs and (D) genes in intervertebral disc degeneration. circRNA, circular RNA; lncRNA, long noncoding RNA; miRNA, microRNA.
Topological features of DEGs in the protein-protein interaction network.
| A, Degree | |
|---|---|
| DEG | Value |
| MAPK1 | 86 |
| JUN | 78 |
| TOP2B | 75 |
| TGFB1 | 70 |
| FOS | 58 |
| BTRC | 49 |
| FN1 | 49 |
| H2AFV | 44 |
| SOCS3 | 43 |
| POLR2C | 43 |
| UBE2C | 43 |
| CDC23 | 42 |
| VIM | 42 |
| KEAP1 | 41 |
| MMP2 | 40 |
| ANAPC1 | 40 |
| SKP2 | 40 |
| HIST2H3A | 40 |
| SMAD3 | 39 |
| ENO2 | 39 |
| SMAD2 | 38 |
| CDC26 | 38 |
| UBE2G1 | 37 |
| H2AFX | 37 |
| CSF2 | 37 |
| ENO1 | 37 |
| HIST2H2AA3 | 36 |
| UBE2R2 | 36 |
| HIST1H2BK | 36 |
| PPP2R1A | 36 |
| SIAH1 | 36 |
| RPSA | 36 |
| FAU | 35 |
| HERC3 | 34 |
| HIF1A | 33 |
| ST6GALNAC1 | 1.0000 |
| OTOP3 | 1.0000 |
| ZDHHC9 | 1.0000 |
| HID1 | 1.0000 |
| TMEM128 | 1.0000 |
| RAPH1 | 1.0000 |
| LANCL1 | 1.0000 |
| CAMTA1 | 1.0000 |
| DPP10 | 1.0000 |
| GTF2H2C | 1.0000 |
| BRD9 | 1.0000 |
| ST6GALNAC4 | 0.6667 |
| SLC25A43 | 0.6667 |
| ORMDL1 | 0.6667 |
| GALNT1 | 0.6667 |
| JUN | 0.4257 |
| MAPK1 | 0.4250 |
| FOS | 0.4001 |
| TGFB1 | 0.3967 |
| TOP2B | 0.3917 |
| VIM | 0.3842 |
| FN1 | 0.3766 |
| MMP2 | 0.3762 |
| POLR2C | 0.3760 |
| SMAD3 | 0.3752 |
| YBX1 | 0.3748 |
| ENO1 | 0.3726 |
| HIF1A | 0.3726 |
| ACTL6A | 0.3720 |
| HBA1 | 0.3714 |
| ENO2 | 0.3707 |
| H2AFV | 0.3674 |
| H2AFX | 0.3674 |
| SMAD2 | 0.3668 |
| PPP2R1A | 0.3651 |
| ST6GALNAC1 | 1.0000 |
| ZDHHC9 | 1.0000 |
| MAPK1 | 0.1255 |
| TOP2B | 0.0988 |
| JUN | 0.0913 |
| TGFB1 | 0.0619 |
| FOS | 0.0450 |
| NME2 | 0.0413 |
| FN1 | 0.0365 |
| PPP2R1A | 0.0319 |
| VIM | 0.0314 |
| POLR2C | 0.0310 |
| RAD51 | 0.0301 |
| HIF1A | 0.0293 |
| CTSD | 0.0272 |
| ENO2 | 0.0266 |
| ACTG2 | 0.0253 |
| ENO1 | 0.0242 |
| NDUFA4 | 0.0239 |
| H2AFV | 0.0227 |
| MMP2 | 0.0224 |
| SNCA | 0.0209 |
| SOCS3 | 0.0205 |
| CSF2 | 0.0201 |
| HBA1 | 0.0200 |
| DCN | 0.0199 |
| HLA-DRB1 | 0.0195 |
| BTRC | 0.0182 |
| TGFBR2 | 0.0182 |
| DICER1 | 0.0182 |
| COL1A2 | 0.0181 |
| HIST2H3A | 0.0180 |
| ATF4 | 0.0180 |
| ACTL6A | 0.0170 |
| GNG4 | 0.0166 |
| ST6GALNAC1 | 1.0000 |
| ZDHHC9 | 1.0000 |
| OTOP3 | 1.0000 |
| HID1 | 1.0000 |
| TMEM128 | 1.0000 |
| RAPH1 | 1.0000 |
| LANCL1 | 1.0000 |
| CAMTA1 | 1.0000 |
| DPP10 | 1.0000 |
| GTF2H2C | 1.0000 |
| BRD9 | 1.0000 |
| ST6GALNAC4 | 1.5000 |
| SLC25A43 | 1.5000 |
| ORMDL1 | 1.5000 |
| GALNT1 | 1.5000 |
| JUN | 2.3489 |
| MAPK1 | 2.3532 |
| FOS | 2.4993 |
| TGFB1 | 2.5206 |
| TOP2B | 2.5532 |
| VIM | 2.6028 |
| FN1 | 2.6553 |
| MMP2 | 2.6582 |
| POLR2C | 2.6596 |
| SMAD3 | 2.6652 |
| YBX1 | 2.6681 |
| HIF1A | 2.6837 |
| ENO1 | 2.6837 |
| ACTL6A | 2.6879 |
| HBA1 | 2.6922 |
| ENO2 | 2.6979 |
| H2AFV | 2.7220 |
| H2AFX | 2.7220 |
| SMAD2 | 2.7262 |
| PPP2R1A | 2.7390 |
Value refers to degree, CC, BC or APL, accordingly. APL, average path length; BC, betweenness centrality; CC, closeness centrality; DEGs, differentially expressed genes.
Overlapping DEGs according to topological features (degree, closeness centrality, betweenness centrality and average path length).
| DEG | logFC | FDR |
|---|---|---|
| TOP2B | −2.97 | 1.72×10−6 |
| MMP2 | −2.56 | 1.58×10−3 |
| ENO1 | 2.43 | 1.3×10−6 |
| FOS | 2.32 | 2.18×10−6 |
| MAPK1 | 2.38 | 1.45×10−3 |
| HIF1A | 2.97 | 4.53×10−4 |
| PPP2R1A | 2.15 | 2.3×10−7 |
| ENO2 | 3.37 | 1.04×10−5 |
| POLR2C | 3.01 | 2.00×10−7 |
| TGFB1 | 2.75 | 3.80×10−5 |
| FN1 | 4.69 | 2.90×10−5 |
| JUN | 2.22 | 1.05×10−6 |
| VIM | 5.26 | 1.13×10−9 |
| H2AFV | 2.16 | 3.41×10−4 |
Positive logFC values refer to upregulated expression in samples compared with in control samples; negative logFC values refer to downregulated expression in IDD samples compared with in control samples. DEGs, differentially expressed genes; FC, fold change; FDR, false discovery rates; IDD, intervertebral disc degeneration.
Figure 2.Modules extracted from the protein-protein interaction network. (A) Module 1; (B) module 2; (C) module 3; (D) module 4; (E) module 5; and (F) module 6. Red represents upregulated expression, whereas green represents downregulated expression. The larger the size of the node (protein), the higher its degree (number of interactions). Hub genes are indicated by red boxes.
KEGG pathway analysis of genes in modules.
| A, Module 1 | ||
|---|---|---|
| Term | P-value | Genes |
| hsa04120: Ubiquitin mediated proteolysis | 1.09×10−23 | ANAPC1, SOCS3, BTRC, UBE2G1, FBXO2, SKP2, CDC23, HERC3, KEAP1, UBE2C, CDC26, UBE2R2, FBXW8, CUL7, SIAH1 |
| hsa04114: Oocyte meiosis | 1.51×10−3 | ANAPC1, BTRC, CDC23, CDC26 |
| hsa04110: Cell cycle | 2.19×10−3 | ANAPC1, SKP2, CDC23, CDC26 |
| hsa04914: Progesterone-mediated oocyte maturation | 1.48×10−2 | ANAPC1, CDC23, CDC26 |
| hsa03010: Ribosome | 1.39×10−9 | RPSA, RPS27, RPS29, RPL41, RPL13, RPL31, RPL15, FAU, RPL36, RPS15A, RPS20 |
| hsa04062: Chemokine signaling pathway | 4.75×10−5 | CXCL1, CCR7, PPBP, ADCY7, CXCL2, PF4, CCL5, GNG4 |
| hsa03040: Spliceosome | 5.30×10−3 | BCAS2, HNRNPK, SRSF6, PCBP1, HNRNPU |
| hsa04060: Cytokine-cytokine receptor interaction | 7.15×10−3 | VEGFC, CCR7, PPBP, PF4, CCL5, TGFB1 |
| hsa03015: mRNA surveillance pathway | 1.24×10−2 | PABPN1, PPP2R1A, UPF2, RNPS1 |
| hsa04974: Protein digestion and absorption | 6.15×10−9 | COL4A3, COL9A3, COL4A1, COL1A2, COL2A1, COL5A3 |
| hsa04512: ECM-receptor interaction | 7.97×10−7 | COL4A3, COL4A1, COL1A2, COL2A1, COL5A3 |
| hsa05146: Amoebiasis | 1.77×10−6 | COL4A3, COL4A1, COL1A2, COL2A1, COL5A3 |
| hsa04510: Focal adhesion | 2.50×10−5 | COL4A3, COL4A1, COL1A2, COL2A1, COL5A3 |
| hsa04151: PI3K-Akt signaling pathway | 1.90×10−4 | COL4A3, COL4A1, COL1A2, COL2A1, COL5A3 |
| hsa04611: Platelet activation | 6.93×10−3 | COL1A2, COL2A1, COL5A3 |
| hsa05322: Systemic lupus erythematosus | 1.58×10−5 | HIST2H3A, HIST2H2AA3, H2AFV, HIST1H2BK, H2AFX |
| hsa05034: Alcoholism | 4.74×10−5 | HIST2H3A, HIST2H2AA3, H2AFV, HIST1H2BK, H2AFX |
| hsa05323: Rheumatoid arthritis | 5.45×10−3 | CSF2, FOS, TNFSF11 |
| hsa05200: Pathways in cancer | 1.19×10−2 | FOS, FOXO1, FGF13, SMAD2 |
| hsa04068: FoxO signaling pathway | 1.23×10−2 | FOXO1, SMAD2, IL7R |
| hsa05202: Transcriptional misregulation in cancer | 1.89×10−2 | CSF2, FOXO1, GZMB |
| hsa04060: Cytokine-cytokine receptor interaction | 3.40×10−2 | CSF2, TNFSF11, IL7R |
| hsa05166: Human T-cell leukemia virus 1 infection | 4.14×10−2 | CSF2, FOS, SMAD2 |
| hsa04915: Estrogen signaling pathway | 1.68×10−3 | MAPK1, SHC1, HSPA1B, MMP2 |
| hsa04510: Focal adhesion | 1.30×10−2 | MAPK1, PGF, FLT4, SHC1 |
| hsa04015: Rap1 signaling pathway | 1.37×10−2 | MAPK1, PGF, FLT4, ITGAM |
| hsa04014: Ras signaling pathway | 1.67×10−2 | MAPK1, PGF, FLT4, SHC1 |
KEGG pathways were predicted using the Database for Annotation, Visualization and Integrated Discovery online tool (version 6.8; david.abcc.ncifcrf.gov) (26). KEGG, Kyoto Encyclopedia of Genes and Genomes.
Figure 3.miRNA-mRNA interaction network. Red represents upregulated expression, whereas green represents downregulated expression. Triangular nodes represent miRNAs and oval nodes represent mRNAs. Hub genes are indicated by red boxes. FC, fold change; miRNA/miR, microRNA.
KEGG pathway analysis of genes in regulatory networks.
| A, miRNA-mRNA network | ||
|---|---|---|
| Term | P-value | Genes |
| hsa04350: TGF-beta signaling pathway | 2.02×10−4 | MAPK1, ACVR1B, LTBP1, FST, TGFBR2, SMAD2, TGFB1 |
| hsa04120: Ubiquitin mediated proteolysis | 1.80×10−3 | WWP2, SOCS3, UBE2G1, CDC23, SIAH1, HERC3, UBE2R2 |
| hsa04520: Adherens junction | 2.98×10−3 | MAPK1, ACVR1B, TGFBR2, SMAD2, SNAI1 |
| hsa04010: MAPK signaling pathway | 5.07×10−3 | MAPK1, FOS, ACVR1B, TGFBR2, MKNK2, FGF13, AKT3, TGFB1, ATF2 |
| hsa04115: p53 signaling pathway | 8.57×10−3 | CCND2, SIAH1, MDM4, SESN3 |
| hsa00051: Fructose and mannose metabolism | 9.51×10−3 | PFKFB2, AKR1B1, PMM1 |
| hsa04110: Cell cycle | 1.24×10−2 | CCND2, CDC23, SMAD2, TGFB1, STAG2 |
| hsa04150: mTOR signaling pathway | 1.89×10−2 | MAPK1, HIF1A, AKT3 |
| hsa04620: Toll-like receptor signaling pathway | 2.02×10−2 | MAPK1, FOS, TOLLIP, AKT3 |
| hsa04662: B cell receptor signaling pathway | 3.20×10−2 | MAPK1, FOS, AKT3 |
| hsa04660: T cell receptor signaling pathway | 4.97×10−2 | MAPK1, FOS, AKT3 |
| hsa04350: TGF-beta signaling pathway | 2.36×10−4 | ACVR1B, MAPK1, LTBP1, FST, TGFBR2, SMAD2, BAMBI, TGFB1 |
| hsa04068: FoxO signaling pathway | 8.21×10−4 | MAPK1, SGK3, CCND2, TGFBR2, FOXO1, SMAD2, KLF2, TGFB1, AKT3 |
| hsa04668: TNF signaling pathway | 2.07×10−2 | MAPK1, FOS, CEBPB, SOCS3, AKT3, ATF2 |
| hsa04931: Insulin resistance | 2.22×10−2 | SOCS3, TRIB3, FOXO1, MLXIP, AKT3, NR1H3 |
| hsa05202: Transcriptional misregulation in cancer | 3.90×10−2 | CEBPB, CCND2, TGFBR2, FOXO1, WHSC1, PBX3, EWSR1 |
| hsa04350: TGF-beta signaling pathway | 4.18×10−4 | MAPK1, ACVR1B, LTBP1, FST, TGFBR2, SMAD2, TGFB1 |
| hsa04520: Adherens junction | 1.11×10−2 | MAPK1, ACVR1B, TGFBR2, SMAD2, SNAI1 |
| hsa04120: Ubiquitin mediated proteolysis | 1.93×10−2 | SOCS3, UBE2G1, CDC23, SIAH1, HERC3, UBE2R2 |
| hsa04115: p53 signaling pathway | 4.19×10−2 | CCND2, SIAH1, MDM4, SESN3 |
| hsa04110: Cell cycle | 4.53×10−2 | CCND2, CDC23, SMAD2, TGFB1, STAG2 |
| hsa05220: Chronic myeloid leukemia | 4.53×10−2 | MAPK1, ACVR1B, TGFBR2, TGFB1 |
| hsa04010: MAPK signaling pathway | 4.82×10−2 | MAPK1, FOS, ACVR1B, TGFBR2, MKNK2, FGF13, TGFB1 |
| hsa04350: TGF-beta signaling pathway | 7.61×10−4 | ACVR1B, LTBP1, FST, TGFBR2, SMAD2, TGFB1 |
| hsa04068: FoxO signaling pathway | 5.92×10−3 | CCND2, TGFBR2, FOXO1, SMAD2, KLF2, TGFB1 |
| hsa05202: Transcriptional misregulation in cancer | 1.49×10−2 | CCND2, TGFBR2, FOXO1, WHSC1, PBX3, EWSR1 |
| hsa04144: Endocytosis | 4.72×10−2 | TGFBR2, CYTH4, RUFY1, SMAD2, CYTH3, TGFB1 |
| hsa04110: Cell cycle | 4.92×10−2 | CCND2, SMAD2, TGFB1, STAG2 |
KEGG pathway analysis was conducted using the Database for Annotation, Visualization and Integrated Discovery online tool (version 6.8; david.abcc.ncifcrf.gov) (26). ceRNAs, competing endogenous RNAs; circRNA, circular RNA; KEGG, Kyoto Encyclopedia of Genes and Genomes; lncRNA, long noncoding RNA; miRNA, microRNA.
Figure 4.Competing endogenous RNA interaction network of lncRNA-miRNA-mRNA. Red represents upregulated expression, whereas green represents downregulated expression. Square nodes represent lncRNAs, triangular nodes represent miRNAs and oval nodes represent mRNAs. Hub genes are indicated by red boxes. FC, fold change; lncRNA, long noncoding RNA; miRNA/miR, microRNA.
Figure 5.Competing endogenous RNA interaction network of circRNA-miRNA-mRNA. Red represents upregulated expression, whereas green represents downregulated expression. Diamond nodes represent circRNAs, triangular nodes represent miRNAs and oval nodes represent mRNAs. Hub genes are indicated by red boxes. circRNA, circular RNA; FC, fold change; miRNA/miR, microRNA.
Figure 6.Integrated competing endogenous RNA interaction network of lncRNA/circRNA-miRNA-mRNA. Red represents upregulated expression, whereas green represents downregulated expression. Diamond nodes represent circRNAs, square nodes represent lncRNAs, triangular nodes represent miRNAs and oval nodes represent mRNAs. Hub genes are indicated by red boxes. circRNA, circular RNA; FC, fold change; lncRNA, long noncoding RNA; miRNA/miR, microRNA.
Figure 7.IDD-related competing endogenous RNA interaction network of lncRNA/circRNA-miRNA-mRNA. Diamond nodes represent circRNAs, triangular nodes represent miRNAs, oval nodes represent mRNAs, and hexagons represent overlapped pathways identified in the present study and present in the IDD-related pathway collected from the Comparative Toxicogenomics Database. Hub genes are indicated by red boxes. FC, fold change; circRNA, circular RNA; FC, fold change; IDD, intervertebral disc degeneration; lncRNA, long noncoding RNA; miRNA/miR, microRNA.